These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|---|---|---|
VANGUARD GROUP INC | 9,637,017 | 2,153,680,560 | |
DIAMOND HILL CAPITAL MANAGEMENT INC | 1,978,686 | 442,196,747 | |
GEODE CAPITAL MANAGEMENT, LLC | 1,964,743 | 437,560,596 | |
Allspring Global Investments Holdings, LLC | 1,865,460 | 416,892,944 | |
FMR LLC | 1,586,397 | 354,528,041 | |
DIMENSIONAL FUND ADVISORS LP | 1,367,430 | 305,578,953 | |
Meridiem Investment Management Ltd. | 1,217,560 | 272,113,283 | |
NORDEA INVESTMENT MANAGEMENT AB | 1,052,927 | 243,320,900 | |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 914,019 | 204,264,965 | |
AMERICAN CENTURY COMPANIES INC | 826,022 | 184,599,675 | |
Legal & General Group Plc | 762,340 | 170,367,791 | |
Thrivent Financial for Lutherans | 749,268 | 167,447 | |
Nuveen Asset Management, LLC | 745,124 | 166,520,312 | |
Select Equity Group, L.P. | 635,976 | 142,127,916 | |
LORD, ABBETT & CO. LLC | 627,838 | 140,309 | |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 577,189 | 128,990,198 | |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 549,386 | 122,776,783 | |
BRANDES INVESTMENT PARTNERS, LP | 501,722 | 112,124,826 | |
Alyeska Investment Group, L.P. | 465,337 | 103,993,513 | |
ARIEL INVESTMENTS, LLC | 410,720 | 91,787,706 | |
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 392,880 | 87,800,822 | |
FIL Ltd | 392,367 | 87,686,177 | |
California Public Employees Retirement System | 351,438 | 78,539,364 | |
DEUTSCHE BANK AG\ | 350,472 | 78,323,482 | |
EARNEST PARTNERS LLC | 347,080 | 77,565,439 | |
WELLINGTON MANAGEMENT GROUP LLP | 326,983 | 73,074,160 | |
THOMPSON SIEGEL & WALMSLEY LLC | 318,747 | 71,234 | |
GLENMEDE TRUST CO NA | 295,354 | 66,005,710 | |
NATIXIS ADVISORS, LLC | 291,923 | 65,239 | |
ENVESTNET ASSET MANAGEMENT INC | 284,709 | 63,626,704 | |
River Road Asset Management, LLC | 284,097 | 63,489,998 | |
Qube Research & Technologies Ltd | 278,736 | 62,291,921 | |
CAMBIAR INVESTORS LLC | 275,642 | 61,600,474 | |
AQR CAPITAL MANAGEMENT LLC | 256,698 | 57,158,878 | |
MILLENNIUM MANAGEMENT LLC | 255,808 | 57,167,972 | |
AMUNDI | 252,506 | 53,697,926 | |
CITADEL ADVISORS LLC | 252,248 | 56,372,383 | |
Swiss National Bank | 250,220 | 55,919,166 | |
WEITZ INVESTMENT MANAGEMENT, INC. | 236,350 | 52,819,498 | |
BARTLETT & CO. WEALTH MANAGEMENT LLC | 211,920 | 47,360,059 | |
NICHOLAS COMPANY, INC. | 184,445 | 41,219,769 | |
HSBC HOLDINGS PLC | 176,872 | 39,481,304 | |
Sio Capital Management, LLC | 173,293 | 38,727,520 | |
Cannell & Spears LLC | 170,296 | 38,057,750 | |
DAVIDSON INVESTMENT ADVISORS | 159,271 | 35,593,847 | |
National Pension Service | 159,040 | 35,542,259 | |
NEW YORK STATE COMMON RETIREMENT FUND | 156,046 | 34,873 | |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 155,472 | 34,744,883 | |
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 150,280 | 33,584,574 | |
Bridgewater Associates, LP | 149,878 | 33,494,735 | |
WEDGE CAPITAL MANAGEMENT L L P/NC | 142,968 | 31,950,489 | |
Birch Hill Investment Advisors LLC | 140,358 | 31,367,224 | |
Sequoia Financial Advisors, LLC | 135,413 | 30,262,171 | |
Allianz Asset Management GmbH | 130,812 | 29,233,866 | |
BNP PARIBAS FINANCIAL MARKETS | 126,777 | 28,332,124 | |
RAYMOND JAMES & ASSOCIATES | 124,336 | 27,786,596 | |
Woodline Partners LP | 120,261 | 26,875,928 | |
Mitsubishi UFJ Asset Management Co., Ltd. | 119,688 | 26,747,874 | |
PRICE T ROWE ASSOCIATES INC /MD/ | 118,165 | 26,408 | |
Hunter Perkins Capital Management, LLC | 117,775 | 26,320 | |
CLIFFORD SWAN INVESTMENT COUNSEL LLC | 96,382 | 21,539,425 | |
KBC Group NV | 94,808 | 21,188 | |
Ironvine Capital Partners, LLC | 92,410 | 20,651,787 | |
SCOTIA CAPITAL INC. | 90,377 | 20,197,229 | |
Galvin, Gaustad & Stein, LLC | 88,510 | 19,780,212 | |
EQUITABLE TRUST CO | 87,787 | 19,618,638 | |
ZACKS INVESTMENT MANAGEMENT | 87,703 | 19,599,927 | |
Burgundy Asset Management Ltd. | 86,757 | 19,388,454 | |
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 86,567 | 19,345,993 | |
AMF Tjanstepension AB | 86,026 | 19,231,873 | |
MCRAE CAPITAL MANAGEMENT INC | 83,151 | 18,582,621 | |
Cerity Partners LLC | 81,694 | 18,257,144 | |
Sycale Advisors (NY) LLC | 80,180 | 17,918,626 | |
abrdn plc | 76,999 | 17,142,287 | |
Stack Financial Management, Inc | 75,985 | 16,981,143 | |
JANE STREET GROUP, LLC | 71,627 | 16,007,202 | |
Railway Pension Investments Ltd | 71,300 | 15,934,124 | |
NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 69,460 | 15,523 | |
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 67,491 | 302 | |
Walleye Capital LLC | 67,201 | 15,018,079 | |
LATHROP INVESTMENT MANAGEMENT CORP | 67,132 | 15,003 | |
Brandywine Global Investment Management, LLC | 63,820 | 13,839,367 | |
Mill Capital Management, LLC | 63,151 | 14,112,986 | |
D. E. Shaw & Co., Inc. | 61,583 | 13,762,569 | |
Busey Bank | 61,419 | 13,725,786 | |
BROWN ADVISORY INC | 60,176 | 13,448,030 | |
RENAISSANCE TECHNOLOGIES LLC | 59,205 | 13,231,133 | |
NEEDHAM INVESTMENT MANAGEMENT LLC | 58,863 | 13,154,703 | |
Leeward Investments, LLC - MA | 58,591 | 13,093,819 | |
FINANCIAL COUNSELORS INC | 57,555 | 12,862,391 | |
Swedbank AB | 56,884 | 12,712,436 | |
Clearstead Advisors, LLC | 56,391 | 12,602,165 | |
Channing Capital Management, LLC | 55,452 | 12,392,413 | |
VICTORY CAPITAL MANAGEMENT INC | 55,353 | 12,370,288 | |
STATE OF WISCONSIN INVESTMENT BOARD | 55,198 | 12,335,649 | |
TEACHER RETIREMENT SYSTEM OF TEXAS | 53,465 | 11,948 | |
FIRST TRUST ADVISORS LP | 51,759 | 11,567,098 | |
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 51,000 | 11,397,480 | |
GABELLI FUNDS LLC | 50,585 | 11,304,736 | |
ASSETMARK, INC | 50,224 | 11,224,053 |
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Richelle P. Parham Independent Director Age: 56 Director Since: February 2016 Professional Highlights: Richelle P. Parham has served as a director of the Company since February 2016 and Chairperson of the Compensation and Human Capital Management Committee since June 2023. Ms. Parham currently serves as the President of Global E-Commerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held since June 2021. Prior to Universal Music Group, Ms. Parham served as a Managing Director of WestRiver Group, which is a collaboration of leading investment firms that provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors from October 2019 to May 2021. She is also currently a Strategic Advisor at Camden Partners, a private equity firm, where she previously served as a General Partner from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Vice President, Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for eBay brand strategy and brand marketing, to reach over 108+ million active eBay users, Internet marketing and for customer relationship management. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa, Inc. from 2008 to 2010. Ms. Parham founded and serves as Executive Chairman of the Board of Directors for Shyn, an oral care product company since January 2018. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office. Ms. Parham holds Bachelor of Science degrees in Business Administration and Design Arts from Drexel University. Skills and Qualifications: • Extensive senior-level executive experience, including in corporate finance, and mergers and acquisitions • More than 20 years of global strategy and marketing experience, as well as expertise in understanding consumers and the consumer decision journey | |||
Peter M. Neupert Independent Director Age: 68 Director Since: January 2013 Professional Highlights: Peter M. Neupert has served as a director of the Company since January 2013. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. In addition, Mr. Neupert was a member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2012, a workshop dedicated to transforming the way evidence on clinical effectiveness is generated and used to improve health and healthcare. Mr. Neupert also served on the U.S. President’s Information Technology Advisory Committee, co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert holds an M.B.A. from the Tuck School of Business at Dartmouth College and a B.A. in Philosophy from Colorado College. Skills and Qualifications: • Expertise in health information technology and how to grow shareholder value leveraging business strategies with technology • Audit Committee financial expert • Corporate governance and business strategy expertise • Expertise and experience in cybersecurity matters | |||
Paul B. Rothman, M.D. Independent Director Age: 65 Director Since: June 2023 Professional Highlights: Paul B. Rothman has served as a director of the Company and member of the Quality and Compliance Committee since June 2023. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman holds a Bachelor of Science in biology from the Massachusetts Institute of Technology and an M.D. from Yale University. Skills and Qualifications: • Extensive expertise in patient care, science, and medicine relevant to the clinical laboratory business • Operational, management, and executive leadership experience • Deep understanding of the complexity of the U.S. healthcare delivery system and policy development | |||
Richelle P. Parham Independent Director Age: 56 Director Since: February 2016 Professional Highlights: Richelle P. Parham has served as a director of the Company since February 2016 and Chairperson of the Compensation and Human Capital Management Committee since June 2023. Ms. Parham currently serves as the President of Global E-Commerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held since June 2021. Prior to Universal Music Group, Ms. Parham served as a Managing Director of WestRiver Group, which is a collaboration of leading investment firms that provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors from October 2019 to May 2021. She is also currently a Strategic Advisor at Camden Partners, a private equity firm, where she previously served as a General Partner from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Vice President, Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for eBay brand strategy and brand marketing, to reach over 108+ million active eBay users, Internet marketing and for customer relationship management. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa, Inc. from 2008 to 2010. Ms. Parham founded and serves as Executive Chairman of the Board of Directors for Shyn, an oral care product company since January 2018. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office. Ms. Parham holds Bachelor of Science degrees in Business Administration and Design Arts from Drexel University. Skills and Qualifications: • Extensive senior-level executive experience, including in corporate finance, and mergers and acquisitions • More than 20 years of global strategy and marketing experience, as well as expertise in understanding consumers and the consumer decision journey | |||
Kirsten M. Kliphouse Independent Director Age: 57 Director Since: October 2022 Professional Highlights: Kirsten M. Kliphouse has served as a director of the Company since October 2022. Ms. Kliphouse previously served as the President of Google Cloud Americas, a position she held from March 2022 to July 2023, where she was responsible for leading and growing the sales, go-to-market, customer engagement, channel, and services organizations. At Google Cloud, she also served as the Global Chair of the Aspiring Leadership Academy and Women@Google Cloud. Prior to her position as President, Ms. Kliphouse served as President of the North American division of Google Cloud from June 2019 to March 2022. Prior to Google Cloud, Ms. Kliphouse was Senior Vice President at Red Hat, Inc., a subsidiary of International Business Machines Corporation, Chief Executive Officer of Yardarm Technologies, a hardware and software solutions company, and founder and Chief Executive Officer of Scaling Ventures, a technology investment and advisory firm. Prior to her position at Yardarm, Ms. Kliphouse spent more than 25 years at Microsoft, Inc., where she was part of the executive leadership team and held numerous executive positions in Enterprise Sales, Original Equipment Manufacturers (OEM), Partner and Channels, and as Corporate Vice President of Customer Support, Success and Professional Services, during which she led more than 10,000-employees globally. Ms. Kliphouse is a recipient of the Founders Award for her superior leadership and contributions to the business. Ms. Kliphouse holds a degree in Computer Information Sciences and Business from Muhlenberg College. Skills and Qualifications: • Global cybersecurity incident response and remediation • Executive leadership experience including by delivering operational and financial results • Depth of experience within the technology sector, mergers and acquisitions, and business development • CERT Certificate in Cybersecurity Oversight | |||
Kerrii B. Anderson Independent Director Age: 66 Director Since: May 2006 Professional Highlights: Kerrii B. Anderson has served as a director of the Company since May 2006. Ms. Anderson was Chief Executive Officer of Wendy’s International, Inc., a restaurant operating and franchising company, from April 2006 until September 2008, when the company was merged with Triarc. Ms. Anderson served as Executive Vice President and Chief Financial Officer of Wendy’s International from 2000 to 2006. Prior to this position, she was Chief Financial Officer, Senior Vice President of M/I Schottenstein Homes, Inc. from 1987 to 2000. Skills and Qualifications: • Strong record of leadership in operations and strategy • Audit Committee financial expert with CEO and CFO experience • Extensive public company board, governance, and audit committee experience • Extensive financial, mergers and acquisitions, international, talent management, corporate governance and executive compensation experience • CERT Certificate in Cybersecurity Oversight | |||
Kathryn E. Wengel Independent Director Age: 58 Director Since: March 2021 Professional Highlights: Kathryn E. Wengel has served as a director of the Company since March 2021. Ms. Wengel currently serves as Executive Vice President, Chief Technical Operations and Risk Officer, and a member of the Executive Committee of Johnson & Johnson. Since joining Johnson & Johnson in 1988, Ms. Wengel has served in various positions of increasing responsibility across the enterprise, both in the United States and various locations globally, including Executive Vice President and Chief Global Supply Chain Officer from 2018 to January 2023, Worldwide Vice President, Chief Global Supply Chain Officer from March 2014 to July 2018, and Chief Quality Officer from April 2010 to March 2014. Ms. Wengel holds a Bachelor of Science in Civil Engineering and operations research from Princeton University. Skills and Qualifications: • Extensive global experience in managing complex supply chains, operations, and quality and compliance • Knowledge and experience in the healthcare field • Executive leadership experience • Advocate and sponsor of several key diversity initiatives | |||
Jeffrey A. Davis Independent Director Age: 60 Director Since: December 2019 Professional Highlights: Jeffrey A. Davis has served as a director of the Company since December 2019 and Chairman of the Audit Committee since June 2023. Mr. Davis currently serves as the Chief Financial Officer of Dollar Tree, Inc., a leading operator of discount variety stores, a role he has held since October 2022. Prior to his time at Dollar Tree, Inc., Mr. Davis served as Chief Financial Officer of Qurate Retail Group, a leading retailer and media conglomerate comprised of eight retail brands including QVC, HSN and Zulily from October 2018 through August 2022. Prior to Qurate Retail Group, Mr. Davis served as Chief Financial Officer of J. C. Penney Company Inc., a retail company, from July 2017 until September 2018. Prior to joining J. C. Penney, Mr. Davis served as Chief Financial Officer of Darden Restaurants, Inc., a restaurant operator, from July 2015 until March 2016 and Chief Financial Officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015, and in various other positions of increasing responsibility at Walmart U.S. from 2006 to 2013. Mr. Davis’ experience also includes nine years in senior executive roles at Lakeland Tours LLC and McKesson Corporation. Mr. Davis is a certified public accountant and holds a bachelor’s degree in accounting from the Pennsylvania State University and a master’s degree in business administration from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Skills and Qualifications: • Extensive executive leadership experience, including financial management and public company leadership experience as a CFO across multiple industries • Extensive experience in operations, finance, capital structure, and mergers and acquisition • Audit Committee financial expert • Executive sponsor of diversity initiatives | |||
D. Gary Gilliland, M.D., PH.D. Independent Director Age: 69 Director Since: April 2014 Professional Highlights: D. Gary Gilliland has served as a director of the Company since April 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Center, a research organization, since January 2020. From January 2015 to January 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. Skills and Qualifications: • Board-certified in Internal Medicine and Fellowship training in Hematology and Oncology, each at Harvard Medical School • Expertise in cancer genetics and experience working within medical communities ranging from academia to the pharmaceutical industry • Executive experience in clinical research and healthcare finance and mergers and acquisitions | |||
Adam H. Schechter Chairman, President and Chief Executive Officer Age: 59 Director Since: April 2013 Professional Highlights: Adam H. Schechter has served as a director of the Company since April 2013, President and Chief Executive Officer of the Company since November 2019, and Chairman of the Board since May 2020. Prior to that, Mr. Schechter was President of Global Human Health and an Executive Vice President of Merck & Co., Inc., a pharmaceutical company, from 2010 to 2018, where he was a member of Merck’s executive committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter holds a bachelor’s degree in biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from La Salle University in 2021. Skills and Qualifications: • Global and U.S.-focused leadership roles, while at Merck, spanning sales, marketing, and managed markets, as well as business and product development • Deep knowledge of the pharmaceutical and healthcare industries and extensive experience collaborating with many of the industries’ key stakeholders to achieve patient-focused outcomes • CERT Certificate in Cybersecurity Oversight |
Name and Principal Position |
Year |
Salary ($) |
Bonus ($) |
Non-Qualified Stock Options |
Stock Awards ($) |
Non-Equity Incentive Plan Compensation ($) |
Change in Pension Value And Nonqualified Deferred Compensation Earnings ($) |
All Other Compensation ($) |
Total ($) |
||||||||||||||||||||||||||||||||||||
ADAM H. SCHECHTER President and Chief Executive Officer |
2023 | $ | 1,373,692 | $ | - | $ | 2,250,072 | $ | 9,071,320 | $ | 2,346,018 | $ | - | $ | 938,253 | $ | 15,979,355 | ||||||||||||||||||||||||||||
2022 | $ | 1,317,500 | $ | - | $ | 2,142,125 | $ | 9,063,244 | $ | 1,675,221 | $ | - | $ | 729,207 | $ | 14,927,297 | |||||||||||||||||||||||||||||
2021 | $ | 1,277,381 | $ | - | $ | 1,803,330 | $ | 13,236,819 | $ | 3,802,068 | $ | - | $ | 432,007 | $ | 20,551,605 | |||||||||||||||||||||||||||||
GLENN A. EISENBERG Executive Vice President and Chief Financial Officer |
2023 | $ | 805,462 | $ | - | $ | 615,878 | $ | 2,473,816 | $ | 917,054 | $ | - | $ | 144,567 | $ | 4,956,777 | ||||||||||||||||||||||||||||
2022 | $ | 780,500 | $ | - | $ | 586,988 | $ | 6,551,496 | $ | 661,630 | $ | - | $ | 101,879 | $ | 8,682,493 | |||||||||||||||||||||||||||||
2021 | $ | 756,287 | $ | - | $ | 497,470 | $ | 3,660,580 | $ | 1,500,695 | $ | - | $ | 43,676 | $ | 6,458,708 | |||||||||||||||||||||||||||||
BRIAN J. CAVENEY Executive Vice President and President, Early Development and Chief Medical and Scientific Officer |
2023 | $ | 617,635 | $ | - | $ | 432,955 | $ | 1,745,352 | $ | 609,719 | $ | - | $ | 70,782 | $ | 3,476,443 | ||||||||||||||||||||||||||||
2022 | $ | 538,000 | $ | - | $ | 343,045 | $ | 1,440,880 | $ | 641,792 | $ | - | $ | 44,750 | $ | 3,008,467 | |||||||||||||||||||||||||||||
2021 | $ | 521,532 | $ | - | $ | 286,045 | $ | 2,122,324 | $ | 1,034,877 | $ | - | $ | 15,851 | $ | 3,980,629 | |||||||||||||||||||||||||||||
ANITA Z. GRAHAM Executive Vice President and Chief Human Resources Officer |
2023 | $ | 420,000 | $ | 500,000 | $ | 196,708 | $ | 1,012,330 | $ | 405,331 | $ | - | $ | 21,622 | $ | 2,555,991 | ||||||||||||||||||||||||||||
MARK S. SCHROEDER Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer |
2023 | $ | 617,635 | $ | - | $ | 461,625 | $ | 1,892,720 | $ | 718,807 | $ | 13,815 | $ | 90,506 | $ | 3,795,108 | ||||||||||||||||||||||||||||
2022 | $ | 538,000 | $ | - | $ | 343,045 | $ | 1,440,880 | $ | 456,051 | $ | - | $ | 65,079 | $ | 2,843,055 | |||||||||||||||||||||||||||||
2021 | $ | 521,532 | $ | - | $ | 286,045 | $ | 2,112,324 | $ | 1,034,877 | $ | - | $ | 35,851 | $ | 3,990,629 | |||||||||||||||||||||||||||||
PAUL R. KIRCHGRABER Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology |
2023 | $ | 424,038 | $ | - | $ | 410,610 | $ | 1,648,365 | $ | - | $ | - | $ | 2,845,156 | $ | 5,328,169 | ||||||||||||||||||||||||||||
2022 | $ | 630,000 | $ | - | $ | 388,784 | $ | 1,648,375 | $ | 267,036 | $ | - | $ | 82,738 | $ | 3,016,933 | |||||||||||||||||||||||||||||
2021 | $ | 625,838 | $ | - | $ | 286,045 | $ | 2,112,324 | $ | 1,241,852 | $ | - | $ | 155,367 | $ | 4,421,426 | |||||||||||||||||||||||||||||
THOMAS H. PIKE Executive Vice President |
2023 | $ | 528,846 | $ | - | $ | - | $ | 4,129,232 | $ | - | $ | - | $ | 11,240 | $ | 4,669,318 |
No Customers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Schechter Adam H | Director | 87,441 | 0 |
EISENBERG GLENN A | Director | 31,289 | 0 |
BERBERIAN LANCE | EVP, CIO & CTO | 19,697 | 0 |
BERBERIAN LANCE | Director | 15,921 | 0 |
ANDERSON KERRII B | Director | 13,722 | 144 |
Kirchgraber Paul R | CEO, Covance Drug Development | 12,946 | 0 |
Gilliland Dwight Gary | Director | 7,712 | 0 |
van der Vaart Sandra D | EVP, Chief Legal Officer | 7,605 | 0 |
Schroeder Mark S | EVP, Pres Diagnostics & COO | 6,687 | 0 |
Summy Amy B. | Director | 4,318 | 0 |
DiVincenzo Jonathan P. | Director | 3,401 | 0 |
DiVincenzo Jonathan P. | EVP, Pres, Central Labs & Intl | 3,355 | 0 |
van der Vaart Sandra D | Director | 2,670 | 0 |
Wilkinson Peter J | SVP, Chief Accounting Officer | 2,087 | 0 |
Wilkinson Peter J | Director | 2,087 | 0 |
Summy Amy B. | EVP, Chief Marketing Officer | 1,669 | 0 |
Rothman Paul | Director | 717 | 0 |
Bailey Megan D. | Director | 436 | 0 |
Kliphouse Kirsten Marie | Director | 372 | 0 |